Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Roche paid $400 million upfront, plus $115 million on the first anniversary, for ex-China rights to two preclinical ADCs and $15 billion in milestones. Stephen Hansen notes Novartis, Novo and Merck recently signed similar early China deals; Jeff Cranmer says Hanso will run Phase 1A before Roche takes over.

Related Insights

Western pharma firms strategically license assets from Chinese biotechs while leaving China rights with the local partner. This leverages China's faster, cheaper clinical development, as the partner tests the molecule in new indications, generating valuable data that de-risks the asset for the global firm at no extra cost.

A notable trend is the licensing of advanced clinical assets from Chinese biotechs to major global pharmaceutical companies for ex-China rights. Deals like Roche licensing Medilink's Phase 3 ADC and AbbVie licensing Reamgen's Phase 2 bispecific antibody signal China's evolution from a market to a source of high-value, late-stage innovation.

Eli Lilly's deal with Innovent outsources R&D through Phase 2 to China. This leverages China's faster clinical development environment, allowing Lilly to de-risk assets before committing to costly global trials, effectively creating an externalized early-stage pipeline.

Historically, multinational drugmakers sourced clinical-stage oncology antibodies and antibody-drug conjugates from China. Recent multibillion-dollar transactions from Novartis, Merck, and Novo Nordisk signal a shift toward acquiring preclinical-stage assets across diverse disease areas and novel modalities—such as mRNA-encoded T-cell engagers and molecular glues—demonstrating increasing Western confidence in early-stage, potentially first-in-class Chinese discovery.

Through massive government investment in biotech infrastructure, China has become the global hub for early-stage clinical drug development. Both Chinese and Western companies now conduct initial human trials there to move much faster and at a significantly lower cost, giving China a strategic foothold in the pharma value chain.

A trio of significant deals in one week—Novo Nordisk, Merck, and Novartis all partnering with Chinese biotechs—underscores a major trend. Western pharmaceutical giants are now aggressively sourcing early-stage, preclinical assets from China to fuel their global R&D pipelines.

Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.

Big Pharma is increasingly licensing assets from Chinese biotechs, putting the region on par with Europe as a source of innovation. However, outright M&A of Chinese firms is a complete non-starter. This reflects a bifurcated strategy: pharma will partner for assets but avoids the geopolitical and logistical headaches of acquisitions, creating a 'license-only' pipeline from China.

With patent cliffs looming and mature assets acquired, large pharmaceutical companies are increasingly paying billion-dollar prices for early-stage and even preclinical companies. This marks a significant strategic shift in M&A towards accepting higher risk for earlier innovation.

In a major strategic shift, large pharmaceutical companies are increasingly sourcing their M&A pipeline from China. Chinese assets now account for 30-40% of Big Pharma's early-stage acquisitions, up from single digits just a few years ago, primarily because they are significantly cheaper than US or European equivalents.